VKTX Charles A Rowland JR sells $2.1M worth of shares
Oct 29, 2025, 4:35 AM
0.00%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Charles A Rowland JR sold 60,000 shares of VKTX on 27 October at $35.57 per share, worth a total of $2.1M. They now own 30,000 VKTX shares, or a 67% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.